What is HC Wainwright’s Estimate for ARWR FY2026 Earnings?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Analysts at HC Wainwright cut their FY2026 earnings estimates for Arrowhead Pharmaceuticals in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will earn ($4.19) per share for the year, down from their previous estimate of ($3.96). HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2027 earnings at ($3.38) EPS, FY2028 earnings at ($3.40) EPS and FY2029 earnings at ($1.40) EPS.

ARWR has been the subject of several other research reports. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Chardan Capital reiterated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. Piper Sandler cut their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Citigroup cut their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. Finally, Sanford C. Bernstein cut their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $43.33.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $20.76 on Monday. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The company’s fifty day moving average price is $20.73 and its two-hundred day moving average price is $21.98. Arrowhead Pharmaceuticals has a 1-year low of $17.05 and a 1-year high of $36.72. The company has a market cap of $2.58 billion, a price-to-earnings ratio of -4.14 and a beta of 0.97.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director William D. Waddill sold 3,748 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $21.90, for a total value of $82,081.20. Following the transaction, the director now owns 44,125 shares in the company, valued at approximately $966,337.50. This trade represents a 7.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James C. Hamilton sold 32,729 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $648,688.78. Following the completion of the sale, the insider now owns 272,122 shares in the company, valued at approximately $5,393,458.04. This trade represents a 10.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 146,473 shares of company stock valued at $2,937,847 over the last three months. 4.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. R Squared Ltd bought a new position in Arrowhead Pharmaceuticals in the 4th quarter worth about $38,000. Values First Advisors Inc. bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at about $52,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 788 shares during the period. KBC Group NV lifted its stake in Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 1,644 shares during the period. Finally, Quantbot Technologies LP bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at about $149,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.